However, some RA patients are intolerant to MTX and thus are instead treated with other csDMARDs and/or non-TNF inhibitors such as anti-IL6R agents and CTLA4-Ig, which have shown reasonable effectiveness29–31. Here, CTLA4 is linked to rheumatoid arthritis.